A new therapeutic target for atherosclerosis treatment: interview with Uday Saxena. Interviewed by Emma Quigley.
Uday Saxena was appointed Chief Scientific Officer at Dr Reddy's Laboratories in 2000. In this role he provides the leadership and general strategy for the company's drug discovery research into metabolic disorders, cardiovascular disorders, inflammation, cancer and anti-infectives. He is also a member of the company's Senior Management Council. He gained his PhD at the Memorial University of Newfoundland, his thesis covering biochemical and functional characterisation of rat C-reactive protein with respect to lipid, lipoprotein metabolism, atherosclerosis and inflammation. On completing his postdoctoral fellowship at Colombia University, he went onto work on various drug discovery projects as Senior Scientist and Principal Research Scientist at Parke-Davis Warner-Lambert and as Director and Vice-President for preclinical research at AtheroGenics, Inc., before undertaking his current position. Uday Saxena has written over 50 peer-reviewed articles and invited reviews. He is currently on the Editorial Board of two international drug discovery-related journals including Expert Opinion on Therapeutic Targets.
Saxena
Uday
U
D000818:Animals; D050197:Atherosclerosis / Q000188:drug therapy*; D002317:Cardiovascular Agents / Q000008:administration & dosage*; D016503:Drug Delivery Systems / Q000639:trends*; D006801:Humans
D002317:Cardiovascular Agents